NGM120

Clinically, GDF15 has shown potential as a biomarker, offering diagnostic precision and prognostic value, particularly when combined with established markers such as prostate-specific antigen. The review concludes with a discussion on several monoclonal antibodies targeting GDF15 in clinical trials, such as AV-380, NGM120, Visugromab, and AZD8853, highlighting promising strategies for novel therapies and precision medicine.

This review covers key investigational therapies developed over the past five years, with a focus on agents targeting Growth Differentiation Factor 15 (GDF-15), including ponsegromab, AV-380, and NGM120. Additional agents include ghrelin receptor agonists (e.g. anamorelin), anabolic/catabolic modulators (ACM-001), and cannabinoids (ART27.13). The evolving role of low-dose olanzapine is also discussed in the 2023 ASCO guideline update...The lack of standardized endpoints, heterogeneity of the syndrome, and absence of FDA-approved treatments remain major barriers to treatment implementation. Multimodal strategies combining pharmacological treatment with nutritional and rehabilitative support are likely to define future therapeutic success.

P2, N=136, Recruiting, NGM Biopharmaceuticals, Inc | Not yet recruiting --> Recruiting

P2, N=136, Not yet recruiting, NGM Biopharmaceuticals, Inc

P2, N=30, Recruiting, NGM Biopharmaceuticals, Inc. | Not yet recruiting --> Recruiting

P2, N=30, Not yet recruiting, NGM Biopharmaceuticals, Inc.

P1/2, N=90, Completed, NGM Biopharmaceuticals, Inc | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jan 2024 | Trial primary completion date: Jul 2024 --> Sep 2023

P1/2, N=75, Active, not recruiting, NGM Biopharmaceuticals, Inc | Recruiting --> Active, not recruiting